BPBhakti K. Patel

Bhakti K. Patel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bhakti K. Patel has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eligibility for Early Mobilization in Mechanically Ventilated Adults: A Multicenter Study

    by Bhakti K Patel, Kaveri Chhikara, Snigdha Jain, Krysta Wolfe, Chad H Hochberg, Anna K Barker, Nicholas E Ingraham, Patrick G Lyons, Brenna Park-Egan, Catherine A Gao, et al.

    Rationale: Early mobilization of mechanically ventilated patients within 72 hours of intubation is underutilized despite its known clinical benefits. The most cited barrier to implementation is physiologic instability. Objectives: To quantify eligibility for early mobilization across established physiologic criteria in a multicenter cohort of mechanically ventilated adults and estimate the relative impact of structural and process implementation barriers. Methods: Retrospective cohort of adults receiving invasive mechanical ventilation for ≥4 hours across nine CLIF Consortium health systems (2018–2024) and MIMIC-IV (2008–2022). Four physiologic eligibility criteria, from clinical trials (Chicago, TEAM) and consensus guidelines (Green, Yellow), were applied between 8am and 5pm within 72 hours of intubation. Random-effects meta-analysis compared eligibility across criteria and quantified the relative effect of two implementation barriers: weekday-only availability (structural) and 4-hour continuous eligibility (process). Measurements and Main Results: Among 223,281 hospitalizations, 86.9–95.6% met eligibility for mobilization within 72 hours of intubation across all 4 criteria. Compared with Chicago trials criteria, eligibility was reduced under TEAM (SHR 0.782, 95% CI 0.746–0.820) and Green (SHR 0.631, 0.611–0.651) but not Yellow (SHR 0.990, 0.976–1.005). Restricting eligibility to weekdays (structural) or requiring continuous eligibility (process) each reduced eligibility by 26-39% across all four criteria (SHR range 0.61–0.74); imposing both barriers together reduced eligibility by 45-56% (SHR range 0.44-0.55). Conclusions: Most mechanically ventilated adults met physiologic eligibility criteria for early mobilization within 72 hours of intubation. Structural and process barriers, such as staff availability on weekends and sustained eligibility for care coordination, reduced opportunity more potently than physiologic instability alone.

  • Top Cited Papers

    The intensive care medicine research agenda for the management of ICU acquired weakness: a multinational, interprofessional perspective

    by Sabrina Eggmann, Selina M. Parry, Tessa Broadley, Gordon S. Lynch, Amy J. Bongetti, Emma J. Ridley, Elizabeth Ayre, Michael Bailey, Rinaldo Bellomo, Sue Berney, et al.

    Intensive care unit acquired weakness (ICUAW) is common in critically ill patients, contributing to substantial morbidity. Major trials and novel mechanistic findings published over the past years have advanced knowledge for the prevention and treatment of ICUAW. To streamline future research priorities, a multinational, interdisciplinary group of ICU clinicians, researchers, and people with lived experience convened to develop this evidence-based research agenda. Using a stepwise process including a systematic review with meta-analysis, two expert panel meetings, and a two-round modified Delphi method, we identified the top ten research priorities for ICUAW. Our report highlights the lack of reliable prognostic markers and mechanistic understanding that limit early diagnosis and treatment. Current evidence to treat ICUAW supports enhanced physical rehabilitation versus no rehabilitation, while higher dose enterally-delivered protein alone does not improve patient outcomes. However, the direct effects on muscles or appropriate dosing for patients with comorbidities remain largely unknown. The proposed ten key priority research questions integrate pathophysiology, diagnostics, treatment, and follow-up and emphasise personalised medicine and patient-centred outcomes over the continuum of recovery. Future research should focus on early prognostic markers, mechanisms of ICUAW, and identification of treatment responders allowing individualised dosing strategies tailored across the recovery trajectory. Defining meaningful outcomes, improving follow-up care, and integrating patient, family and caregiver priorities are essential. Advancing this agenda will require interdisciplinary collaboration and the use of emerging methods, including artificial intelligence, to support personalised and effective ICUAW care.


  • Open Access

    Fecal metabolite profiling identifies critically ill patients with increased 30-day mortality

    by Alexander P. de Porto, Nicholas P. Dylla, Matthew Stutz, Huaiying Lin, Maryam Khalid, Michael W. Mullowney, Jessica Little, Amber Rose, David Moran, Mary McMillin, et al.

    Critically ill patients admitted to the medical intensive care unit (MICU) have reduced intestinal microbiota diversity and altered microbiome-associated metabolite concentrations. Metabolites produced by the gut microbiota have been associated with survival of patients receiving complex medical treatments and thus might represent a treatable trait to improve clinical outcomes. We prospectively collected fecal specimens, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived fecal metabolites by mass spectrometry from 196 critically ill patients admitted to the MICU for non–COVID-19 respiratory failure or shock to correlate microbiota features and metabolites with 30-day mortality. Microbiota compositions of the first fecal sample after MICU admission did not independently associate with 30-day mortality. We developed a metabolic dysbiosis score (MDS) that uses fecal concentrations of 13 microbiota-derived metabolites, which predicted 30-day mortality independent of known confounders. The MDS complements existing tools to identify patients at high risk of mortality by incorporating potentially modifiable, microbiome-related, independent contributors to host resilience.


  • Open Access

    Fecal Metabolite Quantitation for Rapid Assessment of the Gut Microbiome

    by Michael W. Mullowney, Angelica Moran, Antonio Hernandez, Mary McMillin, Amber Rose, David Moran, Jessica Little, Ann B. Nguyen, Bhakti K. Patel, Christopher J. Lehmann, et al.

    The intestinal microbiome is composed of myriad microbial species that produce metabolites that impact host health. While loss of bacterial species and beneficial metabolites from the fecal microbiome is associated with development of a range of diseases and medical complications, there are currently no diagnostic tests that rapidly identify individuals with microbiome deficiencies. Reduced concentrations of fecal butyrate and deoxycholic acid are associated with adverse clinical outcomes and result from the loss of a subset of health-associated bacterial species. We present a rapid diagnostic test based on 3-nitrophenylhydrazine derivatization and ultrahigh-performance liquid chromatography-mass spectrometry that measures fecal butyrate and deoxycholic acid concentrations as markers of microbiome function. A matrix-matched calibration curve was developed using a simulated fecal mixture to optimize accuracy and facilitate adherence to clinical laboratory regulations. The assay showed an analytical measurement range from 4.3–3030.1 µM (LLOQ = 9.75 µM) for butyrate and from 0.9– 64.9 µM (LLOQ = 0.9 µM) for deoxycholic acid. Precision demonstrated a coefficient of variation <15% at all QC levels tested. The assay can be performed in under an hour from extraction to provision of quantitative results, enabling the rapid identification of patients with defective microbiome function.


  • Pharmacotherapy and Pulmonary Fibrosis Risk After SARS-CoV-2 Infection: A Prospective Nationwide Cohort Study

    by R. Baccile, A. Adegunsoye, T. Best, V. Zaksas, H. Zhang, R. Karnik, B.K. Patel, A. Solomonides, W.F. Parker, J. Solway

  • Helmet noninvasive ventilation in acute hypoxic respiratory failure

    by Kevin G. Buell, Bhakti K. Patel

    Purpose of review: Invasive mechanical ventilation is a lifesaving intervention for patients with severe acute hypoxic respiratory failure (AHRF), but it is associated with neuromuscular, cognitive, and infectious complications. Noninvasive ventilation (NIV) may provide sufficient respiratory support without these complications. The helmet interface for NIV could address concerns raised for the use of NIV as first-line therapy in AHRF. This review will summarize and appraise the current evidence for helmet NIV in AHRF. Recent findings: There are only six randomized controlled trials comparing helmet NIV to standard nasal cannula, facemask NIV, or high-flow nasal oxygen in patients with AHRF. Lower rates of endotracheal intubations and fewer days of mechanical ventilation were reported, with inconsistent findings on patient survival. Facemask NIV may worsen preexisting lung injury, delay intubations, and be inferior at delivering lung protective ventilation strategies compared with mechanical ventilation. The helmet interface could circumvent some of these concerns through the delivery of higher positive end expiratory pressure and more uniform distribution of negative pleural pressure. Summary: There is limited evidence to support or refute the use of helmet NIV in AHRF. Further studies investigating the interface of helmet in NIV as a separate clinical entity are needed.


  • Open Access

    Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure

    by Matthew R. Stutz, Nicholas P. Dylla, Steven D. Pearson, Paola Lecompte-Osorio, Ravi Nayak, Maryam Khalid, Emerald Adler, Jaye Boissiere, Huaiying Lin, William Leiter, et al.

    Respiratory failure and mortality from COVID-19 result from virus- and inflammation-induced lung tissue damage. The intestinal microbiome and associated metabolites are implicated in immune responses to respiratory viral infections, however their impact on progression of severe COVID-19 remains unclear. We prospectively enrolled 71 patients with COVID-19 associated critical illness, collected fecal specimens within 3 days of medical intensive care unit admission, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived metabolites (NCT #04552834). Of the 71 patients, 39 survived and 32 died. Mortality was associated with increased representation of Proteobacteria in the fecal microbiota and decreased concentrations of fecal secondary bile acids and desaminotyrosine (DAT). A microbiome metabolic profile (MMP) that accounts for fecal secondary bile acids and desaminotyrosine concentrations was independently associated with progression of respiratory failure leading to mechanical ventilation. Our findings demonstrate that fecal microbiota composition and microbiota-derived metabolite concentrations can predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection and suggest that the gut-lung axis plays an important role in the recovery from COVID-19.


  • Immediate Effect of Mechanical Ventilation Mode and Sedative Infusion on Measured Diaphragm Thickness

    by Steven D. Pearson, Julie Lin, Matthew R. Stutz, Paola Lecompte-Osorio, Anne S. Pohlman, Krysta S. Wolfe, Jesse B. Hall, John P. Kress, Bhakti K. Patel

    Rationale: In patients who are mechanically ventilated, diaphragm thinning on ultrasound is thought to correlate with diaphragm atrophy and has been associated with prolonged intubation. Factors other than atrophy, however, may cause changes in diaphragm thickness, which may confound studies examining changes in diaphragm thickness over time. Objectives: To determine if changes in the mode of mechanical ventilation or an interruption of sedatives have immediate effects on diaphragm thickness measurements in adult patients in the intensive care unit who are mechanically ventilated. Methods: Adult patients receiving invasive mechanical ventilation for less than 48 hours were included. Diaphragm thickness was measured at end-expiration and peak inspiration using ultrasound while patients were receiving both volume assist–control and pressure-support modes in a randomized crossover fashion. In patients receiving sedatives, additional measurements were taken after an interruption of sedatives. Measurements were compared between modes and on assist–control before and after an interruption of sedatives. Results: Of 85 patients enrolled, 66 had measurements on assist–control and spontaneous modes, and 40 had measurements before and after an interruption of sedatives. End-expiratory diaphragm thickness increased by a median of 0.08 mm after an interruption of sedatives (95% confidence interval [CI], 0.002 mm to 0.164 mm; P = 0.017), corresponding to a median increase of 6.5%. No difference was seen when comparing measurements taken on volume assist–control and pressure support (median difference, 0 mm; 95% CI, −0.07 mm to 0.08 mm; P = 0.98). Conclusions: End-expiratory diaphragm thickness increased by 6.5% after an interruption of sedatives. The effect of sedatives on measured diaphragm thickness should be considered in future studies examining changes in diaphragm thickness over time. Clinical trial registered with Clinicaltrials.gov (NCT04319939).